Pular para o conteúdo
Even3

Combinação de Remdesivir e Topotecan contra a COVID-19

Trecho de 55 s de Pathogen host and immune response, gravado no evento UNESP International Symposium on Covid-19 Research.

Assistir à gravação completaNo Even3 Conteúdos · 2 h 33 min

Sobre este trecho

Apresenta-se a justificativa científica da terapia combinada que une controle da replicação viral e inibição da resposta inflamatória grave no pulmão.

Vai de a da gravação.

O que é dito neste trecho

So this is the summary and you can read some of this in this paper. If we use Tocapide Khan alone, we limit lung inflammation but we increase virus replication and virus dissemination. That's why we need an antiviral treatment. If we use Remdesivir alone, we limit the virus shedding and dissemination but we have no and I don't have data should time to show that but we have no effect on lung inflammation and pneumonia. So you have less virus but you still have inflammation. So that's why we combined Tocapide Khan with Remdesivir and then we have less virus replication and at the at the same time limited lung inflammation. And so we are now in clinical trials with this treatment in Singapore and in India. So this came out of a preclinical animal model and now we are going into humans and we have all the permits to do that.

Outros trechos deste conteúdo